Drugs / SNIPR001
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05277350 Comparator | Mar → Nov 2022 | escherichia coli infection | SNIPR Biome Aps. | Completed | No outcome recorded |
| Phase 1/2 | NCT06938867 Comparator | Feb 2025 → Apr 2026 overdue | escherichia coli infection | SNIPR Biome Aps. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNIPR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277350 ↗ |
| Action | Inhibit | “reduce colonisation of E coli in the gastrointestinal tract” PMID 41785880 ↗ Mar 2026 |
| Modality | CRISPR / gene editing | “Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001” PMID 41785880 ↗ Mar 2026 |
| Route | Oral | “Participants were orally administered 108 plaque-forming units (PFU) per dose (cohort 1), 1010 PFU per dose (cohort 2), and 1012 PFU per dose (cohort 3) of SNIPR001 or placebo...” PMID 41785880 ↗ Mar 2026 |